Announcements Trials
Browse Landscape

Phase

Phase 2 42Phase 3 12Phase 1/2 12Phase 1 11Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Radiotherapy 17Specimen Handling 16Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11fludarabine 9Fluorodeoxyglucose F18 9X-Rays 8Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × niraparib × 1 year × Clear all
NCT05076513 2026-03-09

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Active not recruiting
42 enrolled
CNS

Glioblastoma, Glioma

NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

Massachusetts General Hospital

Phase EARLY_PHASE1 Active not recruiting
16 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡